Corcept raises 2026 revenue guidance to $950M-$1.05B as it targets $2B Cushing’s sales and $1B+ Lifyorli by decade-end
Corcept Therapeutics Inc. · PHARMACEUTICAL PREPARATIONS · Now $70.44
+1.4% in 3d after detection
Post-detection moves
1h
—
1d
+0.4%
3d
+1.4%
7d
-0.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS